Health Care

Pfizer insider confidence: senior execs hold 45K shares and SARs, boosting long‑term growth signals amid market volatility.

OrbiMed’s recent sell‑orders inject fresh liquidity into Adicet Bio, reflecting a strategic recalibration of institutional stakes amid rising investor caution.

Insider sales at Hologic’s merger reveal confidence in the $76 cash payout and hint at a strategic shift under Hopper Parent Inc., affecting future earnings and shareholder value.

Hologic insider sales post‑merger: Stewart Stacey sold 8,358 shares and options after the Hopper deal, signalling a strategic exit, not a downturn. Explore what this means for Hologic’s future and investors.

Vistagen insiders issue 75,000 options, signaling long‑term confidence and a potential rebound for the biotech stock.

GRAIL CFO Freidin Aaron sells 45,806 shares in April 2026: a routine tax‑cover move amid market volatility, not a bearish signal for investors.

Alterity Therapeutics CFO’s new option purchase signals a quiet shift in management outlook, hinting at potential upside as the company nears clinical milestones.

Relay Therapeutics CFO’s disciplined 10b5‑1 sale signals confidence amid a 52‑week high—investors can gauge future upside by tracking insider trades and earnings.

Insider option grants at Vistagen Therapeutics signal executives’ confidence in the stock’s future value, hinting at potential upside amid clinical milestones.

Insider sales at Hologic spike as the company heads to a Blackstone‑TPG takeover—what the timing means for investors and future stock value.